Elkaeed, E.B.; Elkady, H.; Belal, A.; Alsfouk, B.A.; Ibrahim, T.H.; Abdelmoaty, M.; Arafa, R.K.; Metwaly, A.M.; Eissa, I.H.
Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs. Processes 2022, 10, 530.
https://doi.org/10.3390/pr10030530
AMA Style
Elkaeed EB, Elkady H, Belal A, Alsfouk BA, Ibrahim TH, Abdelmoaty M, Arafa RK, Metwaly AM, Eissa IH.
Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs. Processes. 2022; 10(3):530.
https://doi.org/10.3390/pr10030530
Chicago/Turabian Style
Elkaeed, Eslam B., Hazem Elkady, Amany Belal, Bshra A. Alsfouk, Tuqa H. Ibrahim, Mohamed Abdelmoaty, Reem K. Arafa, Ahmed M. Metwaly, and Ibrahim H. Eissa.
2022. "Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs" Processes 10, no. 3: 530.
https://doi.org/10.3390/pr10030530
APA Style
Elkaeed, E. B., Elkady, H., Belal, A., Alsfouk, B. A., Ibrahim, T. H., Abdelmoaty, M., Arafa, R. K., Metwaly, A. M., & Eissa, I. H.
(2022). Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs. Processes, 10(3), 530.
https://doi.org/10.3390/pr10030530